The Pink Agenda has contributed more than two million dollars to fund breast cancer research.
Raising money so that we can improve the lives of those suffering from breast cancer while simultaneously working to improve their odds is a big undertaking. To ensure that we fund the projects and programs that will make a real difference, The Pink Agenda works with some of the world’s foremost authorities on breast cancer to guide our grantmaking. TPA makes two types of grants – research grants and direct care grants.
We rely on the Breast Cancer Research Foundation’s (BCRF) esteemed Scientific Advisory Board (SAB) to guide our research-related grantmaking. Based on the belief that some of the most important advances in understanding the disease will come when we allow brilliant minds to pursue some of their most creative theories, BCRF’s SAB invites select scientists from leading universities and academic medical centers around the world to submit proposals outlining creative new directions in clinical and/or translational research that are in need of seed funding.
Direct Care Grants
The Pink Agenda has also worked with the Dana-Farber Cancer Institute’s Young and Strong Program for Young Women with Breast Cancer to identify projects that have had a direct and positive impact on women’s cancer care. Since it was founded in 2005, Young and Strong has guided more than 3,000 young women on their journeys through and beyond cancer, addressing their needs with comprehensive care and support together with a range of programs tailored specifically for them. In doing so, it has become a model for women’s cancer care across the country.
2018 Grant Recipient
Dr. Ann Partridge
Harvard Medical School
Dana-Farber/Brigham and Women’s Cancer Center
Dana-Farber Cancer Institute
The Pink Agenda’s 2018 Research and Direct Care Award supports the work of Dr. Ann Partridge, the founder and director of Dana-Farber Cancer Institute’s Young and Strong Program for Young Women with Breast Cancer. Her studies are focused on young women initially diagnosed with breast cancer under the age of 40 and cancer survivorship.
Breast cancer is the leading cause of cancer-related deaths in women under the age of 40 in the United States. Dr. Partridge and her team will build on prior research to improve understanding of the complex medical and emotional problems facing young women with breast cancer, with a new focus on intervention and outreach.
The team will design and launch two parallel studies: 1) the Young Women’s Breast Cancer Study 2 (YWS2), which will enroll newly diagnosed young women in their clinical program and 2) the Young Women’s Breast Cancer Study 2-Internet (YWS2i), which will engage a broader population of young breast cancer patients through a web-based platform.
In both studies, the research team will collect medical information and biological specimens and conduct participant surveys and treatment for young women.
Using an innovative navigation strategy, this research will lead not only to new insights to inform future care and research, but will directly enhance the care of young women with breast cancer who are participating in the studies, and serve to accelerate accrual to other studies relevant to this vulnerable population.
Ann Partridge, MD, MPH is a medical oncologist and clinical researcher focused on improving the care and outcomes of patients with cancer, with a focus on treatment, survivorship, and psychosocial issues facing women with breast cancer. She founded and directs the Young and Strong Program for Young Women with Breast Cancer, and serves as the Director of Adult Survivorship at Dana-Farber Cancer Institute (DFCI) and Brigham and Women’s Hospital. She serves on several committees, including as co-Chair of the Alliance for Clinical Trials Breast Committee and Chair for the Federal Advisory Committee to the Center for Disease Control on Breast Cancer in Young Women. Dr. Partridge has published numerous manuscripts and lectures both nationally and internationally on issues of cancer survivorship and young women with breast cancer, in particular and has received grants and awards recognizing her work in this area. Dr. Partridge graduated from Georgetown University, earned her MD at Cornell University, trained in internal medicine at the Hospital of the University of Pennsylvania, and completed hematology and medical oncology fellowships at DFCI. She received a master’s degree in public health at the Harvard School of Public Health.